Skip to main content

Will heparin-bonded PTFE replace autologous venous conduits in infrapopliteal bypass?

Peeters et al., 20081

Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium

Primary patency of GORE® PROPATEN® Vascular Graft

N=75
1 year 81%
2 years 78%
3 years 75%

Patient characteristics

Characteristic N %
Rutherford classification  
3 85 56%
4 29 19%
5 39 25%
Runoff Vessels 10 3%
0 7 5%
1 76 50%
2 43 28%
3 27 18%
Diabetes 37 27%
Hypertension* 88 64%
Coronary artery disease* 42 30%
Nicotine use* 66 48%

Study details

  • Prospective, multi-center study
  • No adjunctive techniques (patches or cuffs) were used in the study
  • 73% of patients had been previously treated for peripheral vascular disease (PVD)
  • The 3-year limb salvage rate for all CLI patients was 86%**

…it is our opinion that the Propaten Vascular Graft [GORE® PROPATEN® Vascular Graft] may succeed in bridging the gap between venous conduits and regular ePTFE grafts. — P. Peeters


* Total N = 138, which includes 97 patients that underwent below-knee bypasses.

** Limb salvage rates are for both above and below-knee bypasses.

† Total N = 153 limbs

1. Peeters P, Verbist J, Deloose K, Bosiers M.  Will heparin-bonded PTFE replace autologous venous conduits in infrapopliteal bypass?  Italian Journal of Vascular & Endovascular Surgery 2008;15(3):143-148.